March 2026
Anxiety
What March 2026's 14 new studies found, synthesized from the papers below. All Anxiety research →
The synthesis
Synthesized from 14 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Anxiety, generalized anxiety disorder, GAD, panic disorder, anxiety disorder, then ranked by relevance.
Research in March 2026 indicates that psychedelic experiences, particularly those involving mystical-type experiences, are associated with moderate-to-large reductions in death anxiety, especially in clinical settings. However, the relationship between psychedelic use and general anxiety is moderated by age, with benefits observed in younger adults but diminishing or reversing in older populations. Evidence is limited by small sample sizes, potential publication bias, and reliance on retrospective or open-label designs.
Confidence in the evidence
Low-Moderate- Only one meta-analysis (8 studies) and one cross-sectional survey (1,088 participants) directly address anxiety, with the meta-analysis showing moderate-to-large effect but potential publication bias.
- The cross-sectional survey found age-dependent effects on anxiety, introducing complexity and inconsistency across populations.
- Most studies are observational, retrospective, or qualitative, lacking rigorous controlled trials specifically for anxiety outcomes.
- Several studies focus on death anxiety or OCD rather than generalized anxiety, limiting direct applicability to the question.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychedelic Experiences and Finitude in Serious Illness: A Qualitative Synthesis 2026 | qualitative systematic review | 9 | Supports | Qualitative synthesis identified a transformation in the relationship with finitude, reducing fear of death and existential distress. |
| Classic psychedelic medicines for adolescent refractory mental health disease 2026 | commentary | Unclear | Commentary advocates for cautious research in adolescents but does not provide new data on anxiety outcomes. | |
| O potencial terapêutico dos psicodélicos no tratamento de distúrbios neuropsiquiátricos 2026 | review | Supports | Review reports that controlled psychedelic use can provide durable relief from anxiety and other neuropsychiatric symptoms. | |
| A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder 2026 | RCT | Supports | Psilocybin significantly reduced OCD severity (73.3% responders) with effects lasting 6 months; no serious adverse events. | |
| Ego Dissolution, Death Anxiety, and Impulse Regulation: A Conceptual Psychological Model of Contemplative Transformation 2026 | theoretical | Supports | Conceptual model proposes that ego dissolution reduces death anxiety and improves impulse regulation. | |
| IMPLEMENTATION OF GOOD AND STRONG CULTURE FOR ISLAMIC MINDFULNESS THERAPY AS AN ALTERNATIVE TO OVERCOMING ANXIETY AND DEPRESSION 2026 | qualitative | Supports | Islamic mindfulness therapy integrating local culture improved resilience and emotional management, reducing anxiety and depression. | |
| Age moderates the relationship between psychedelics use and mental health in naturalistic settings 2026 | cross-sectional survey | 1088 | Mixed | Classic psychedelic use was linked to lower anxiety in younger adults but reversed for anxiety in older participants, with age moderating the effect. |
| Confronting mortality: A meta-analysis and systematic review of psychedelic experiences and death anxiety 2026 | meta-analysis and systematic review | 8 | Supports | Meta-analysis found a moderate-to-large reduction in death anxiety (Cohen's d = 0.70) following psychedelic administration, with stronger effects in clinical settings. |
| Exploring associations between connectedness and death anxiety following a psychedelic experience 2026 | retrospective cross-sectional survey | 106 | Supports | Significant decreases in fear of death and death avoidance were associated with increased connectedness to self, others, and the world. |
| The combination of exercise and psychedelics for the treatment of major depressive disorder 2026 | commentary | Unclear | Commentary discusses potential synergy of exercise and psychedelics for depression but does not directly address anxiety. | |
| Effective doses of esketamine oral or esketamine intranasal for the prevention of preoperative anxiety in pediatric patients: A randomized double-blind dose-finding trial 2026 | RCT | Supports | Esketamine (oral or intranasal) effectively prevented preoperative anxiety in pediatric patients, with determined ED95 doses. | |
| A repeated low-dose regimen of MDMA has transient next-day effects on locomotor activity, anxiety-like behavior, and brain serotonin levels, with no effect on anhedonia-like behavior, in both female and male rats 2026 | preclinical | Mixed | Repeated low-dose MDMA caused transient anxiety-like behavior in rats at 1 day but not 15 days post-administration, with reduced serotonin in nucleus accumbens. | |
| A Blueprint for Implementing Ketamine-Assisted Psychotherapy in Palliative Care: Design, Process, and Treatment Patterns of a Real-World Clinical Program. 2026 | observational program description | 30 | Supports | Ketamine-assisted psychotherapy in palliative care was feasible and may alleviate anxiety and existential distress, though high-level evidence is limited. |
| A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations 2026 | scoping review | 410 | Supports | Mystical-type experiences were associated with reduced anxiety and depression in both life-threatening disease and depressive populations. |
Qualitative synthesis identified a transformation in the relationship with finitude, reducing fear of death and existential distress.
qualitative systematic review Sample size: 9
Commentary advocates for cautious research in adolescents but does not provide new data on anxiety outcomes.
commentary
Review reports that controlled psychedelic use can provide durable relief from anxiety and other neuropsychiatric symptoms.
review
Psilocybin significantly reduced OCD severity (73.3% responders) with effects lasting 6 months; no serious adverse events.
RCT
Conceptual model proposes that ego dissolution reduces death anxiety and improves impulse regulation.
theoretical
Islamic mindfulness therapy integrating local culture improved resilience and emotional management, reducing anxiety and depression.
qualitative
Classic psychedelic use was linked to lower anxiety in younger adults but reversed for anxiety in older participants, with age moderating the effect.
cross-sectional survey Sample size: 1088
Meta-analysis found a moderate-to-large reduction in death anxiety (Cohen's d = 0.70) following psychedelic administration, with stronger effects in clinical settings.
meta-analysis and systematic review Sample size: 8
Significant decreases in fear of death and death avoidance were associated with increased connectedness to self, others, and the world.
retrospective cross-sectional survey Sample size: 106
Commentary discusses potential synergy of exercise and psychedelics for depression but does not directly address anxiety.
commentary
Esketamine (oral or intranasal) effectively prevented preoperative anxiety in pediatric patients, with determined ED95 doses.
RCT
Repeated low-dose MDMA caused transient anxiety-like behavior in rats at 1 day but not 15 days post-administration, with reduced serotonin in nucleus accumbens.
preclinical
Ketamine-assisted psychotherapy in palliative care was feasible and may alleviate anxiety and existential distress, though high-level evidence is limited.
observational program description Sample size: 30
Mystical-type experiences were associated with reduced anxiety and depression in both life-threatening disease and depressive populations.
scoping review Sample size: 410
Points of agreement
- Psychedelic experiences, especially those involving mystical-type experiences, are consistently associated with reductions in death anxiety and existential distress.
- Clinical or controlled settings appear to produce stronger effects on anxiety-related outcomes than naturalistic use.
- Psychedelic-assisted therapies are generally well-tolerated with no serious adverse events reported in the included studies.
Conflicts
- The cross-sectional survey found that classic psychedelic use was associated with lower anxiety in younger adults but reversed for anxiety in older adults, conflicting with the overall positive direction from other studies.
- Preclinical data showed transient anxiety-like behavior in rats after MDMA, contrasting with human studies reporting anxiolytic effects.
Gaps
- No large-scale, double-blind, placebo-controlled RCTs specifically targeting generalized anxiety disorder were identified.
- Durability of anxiety reduction beyond 6 months is not well-studied.
- Adolescent populations remain excluded from clinical trials, limiting generalizability.
- Age as a moderator of anxiety outcomes requires further prospective investigation.
- Standardized outcome measures for death anxiety are lacking, contributing to heterogeneity.